Product Description
SSR97225 is a novel tubulin-binding antimitotic agent with a potential dual mechanism of action possessing both anti-mitotic and anti-vascular activities. (Sourced from: https://ncats.nih.gov/files/SSR97225.pdf)
Mechanisms of Action: Mitosis Inhibitor,Tubulin Binder
Novel Mechanism: Yes
Modality: N/A
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Sanofi
Company Location: PARIS I0 75008
Company CEO: Paul Hudson
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| TED5710 | P1 |
Terminated |
Oncology Solid Tumor Unspecified |
2008-08-01 |